HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.

AbstractBACKGROUND:
Evidence regarding the mortality rate after administration of the pandemic influenza A (H1N1) 2009 vaccine on patients with underlying diseases is currently scarce. We conducted a case-control study in Japan to compare the mortality rates of patients with idiopathic interstitial pneumonia after the vaccines were administered and were not administered.
METHODS:
Between October 2009 and March 2010, we collected clinical records in Japan and conducted a 1:1 matched case-control study. Patients with idiopathic interstitial pneumonia who died during this period were considered case patients, and those who survived were considered control patients. We determined and compared the proportion of each group that received the pandemic influenza A (H1N1) 2009 vaccine and estimated the odds ratio. Finally, we conducted simulations that compensated for the shortcomings of the study associated with adjusted severity of idiopathic interstitial pneumonia.
RESULTS:
The case and control groups each comprised of 75 patients with idiopathic interstitial pneumonia. The proportion of patients who received the pandemic influenza A (H1N1) 2009 vaccine was 30.7% and 38.7% for the case and control groups, respectively. During that winter, the crude conditional odds ratio of mortality was 0.63 (95% confidence interval, 0.25-1.47) and the adjusted conditional odds ratio was 1.18 (95% confidence interval, 0.33-4.49); neither was significant. The simulation study showed more accurate conditional odds ratios of 0.63-0.71.
CONCLUSIONS:
In our study, we detected no evidence that the influenza A (H1N1) 2009 vaccine increased the mortality rate of patients with idiopathic interstitial pneumonia. The results, however, are limited by the small sample size and low statistical power. A larger-scale study is required.
AuthorsHiroshi Yokomichi, Shintaro Kurihara, Tetsuji Yokoyama, Eisuke Inoue, Keiko Tanaka-Taya, Shigeru Kono, Zentaro Yamagata
JournalPloS one (PLoS One) Vol. 9 Issue 2 Pg. e88927 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24586445 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Influenza Vaccines
Topics
  • Aged
  • Case-Control Studies
  • Female
  • Humans
  • Idiopathic Interstitial Pneumonias (immunology, mortality)
  • Influenza A Virus, H1N1 Subtype (immunology)
  • Influenza Vaccines (adverse effects, immunology)
  • Influenza, Human (immunology)
  • Japan
  • Male
  • Mortality
  • Odds Ratio

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: